2012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day. Critical Path Institute , a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does. C-Path Milestones and “firsts” include: 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely. 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data. 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes. 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials. 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials. C-Path brings together stakeholders to create what no one company, university, or government agency could do alone: 6 global consortia with 1,000 scientists, 41 companies, government agencies, patient groups, and academia to collaborate on “tools” to help drug development and focus on drug safety, drug effectiveness, diseases of the brain, developing new imaging biomarkers, and testing drug combinations. C-Path’s collaborative work is just beginning to translate knowledge of disease and human physiology into safe and effective therapies.
AZBio Expo 2011 Company Spotlight
The 2011 AZBio Expo brought together innovative and life saving companies from across the state along with leaders from across the industry. Be sure to check out the highlights and a special spotlight interview where Don Isaacs, VP of Communications at SynCardia Systems, Inc. brings EmpowHER's Shana O'Conner up close and personal with the world's only Total Artificial Heart. It's why SynCardia was named the 2011 Bioscience Company of the Year.
Ventana: The Birth of a Life Changing Idea
Ventana Medical Systems, Inc., a Member of the Roche Group, is a global leader in tissue diagnostic innovations for anatomic pathology. This video reveals the true story of a quest to improve the standard of care for a single patient -- a quest that began a new era in cancer diagnostics. Discover how automated staining is empowering histology labs worldwide to deliver prompt, personalized diagnostic information.
2012 Bioscience Company of the Year - Cord Blood Registry
The first cord blood sample ever saved by a family belonged to the son of CBR's Scientific Director. Two decades later, CBR (Cord Blood Registry) is the largest, most experienced stem cell bank, entrusted by families worldwide. Thanks to expecting families like yours, more than 400,000 children have newborn stem cells saved with CBR. As you decide what's best for your family, it's important to understand the CBR difference in quality and experience. CBR has banked more stem cells than any other family bank and has the most experience helping families use their cord blood for medical treatments. In October 2012, CBR was named the Arizona Bioscience Company of the Year.
CBR - 20 Years of Cord Blood Research
Cord blood stem cells have been used to treat more than 80 diseases, from leukemias and anemias to immune and metabolic disorders. Today, even more treatment options are being evaluated in cutting-edge, FDA-regulated clinical trials. This growing number of potential uses means more medical options for your family later.
Announcing Grants for Emerging Medical Device Companies
Arizona has one of the fastest growing bioscience communities in the US; annual total economic activity is now $28.8 billion. It has a particularly robust medical device sector, which constitutes 32% of Arizona’s non-hospital bioscience employment. With first-class research institutions and an industry spanning from one-person shops to industry giants, Arizona has it all.To support this critically important sector, the City of Peoria, Arizona, BioAccel and The Plaza Companies have created BioInspire™, an incubator in Peoria dedicated to medical device development that provides working capital and space to qualifying companies. More than just a facility, this collaboration was created to connect the medical device community.
Arizona Commerce Authority05/17/2013
AZ Innovation Challenge Video
The Arizona Innovation Challenge (AIC), powered by the Arizona Commerce Authority , awards the most money in the country for a technology commercialization challenge – $3 million ($1.5 million twice yearly) to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company. The results? A big-time investment in the most talented entrepreneurs. Bringing to market products that are literally changing the way the world works. Driving wealth and job creation for the state of Arizona. Are you up for the Challenge?
Biotech TGen Alzheimers Disease Research
The Translational Genomics Research Institute (TGen) is a Phoenix-based nonprofit working with collaborators in the scientific and medical communities to improve the efficiency and effectiveness of gene research, fighting diseases such as cancer, neurological disorders and diabetes. This video features researchers Matthew Huentelman and Travis Dunkley, as well as a few patients.